Profile data is unavailable for this security.
About the company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
- Revenue in USD (TTM)774.20m
- Net income in USD-234.60m
- Incorporated1992
- Employees2.70k
- LocationMyriad Genetics Inc322 North 2200 WestSALT LAKE CITY 84116United StatesUSA
- Phone+1 (801) 584-3600
- Fax+1 (801) 584-3640
- Websitehttps://myriad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | 360.91m | -134.74m | 2.04bn | 436.00 | -- | 2.23 | -- | 5.66 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.05bn | 1.76k | 14.44 | 3.04 | 10.20 | 3.03 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.06bn | 7.70k | -- | -- | 19.39 | 0.8275 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.09bn | 1.54k | -- | -- | -- | 2.10 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.17bn | 186.00 | -- | 3.05 | -- | 27.29 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.17bn | 55.00 | -- | 6.12 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Geron Corp | 520.00k | -201.40m | 2.19bn | 141.00 | -- | 6.30 | -- | 4,220.37 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.20bn | 355.00 | -- | 6.62 | -- | 12.59 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.21bn | 2.70k | -- | 2.90 | -- | 2.85 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.23bn | 624.00 | -- | 14.48 | 466.65 | 7.86 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.26bn | 500.00 | -- | 5.63 | -- | 48.88 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.32bn | 226.00 | -- | 37.63 | -- | 25.21 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -102.40m | 2.35bn | 18.00k | -- | 1.47 | -- | 0.7822 | -1.15 | -1.38 | 33.80 | 17.92 | 0.7027 | -- | 3.10 | -- | -2.39 | -- | -2.89 | -- | 16.64 | -- | -3.41 | -- | -- | 0.0877 | 0.5019 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.36bn | 64.00 | -- | 3.60 | -- | 323.68 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.37bn | 445.00 | -- | 3.88 | -- | 33.26 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Data as of May 22 2024. Currency figures normalised to Myriad Genetics Inc's reporting currency: US Dollar USD
70.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 13.63m | 15.17% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.88m | 11.00% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 8.06m | 8.97% |
| Camber Capital Management LPas of 31 Mar 2024 | 7.64m | 8.50% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.40m | 6.01% |
| Glenview Capital Management LLCas of 31 Mar 2024 | 4.94m | 5.50% |
| Millennium Management LLCas of 25 Apr 2024 | 4.54m | 5.06% |
| EARNEST Partners LLCas of 31 Mar 2024 | 3.93m | 4.38% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 2.70m | 3.01% |
| Artisan Partners LPas of 31 Mar 2024 | 2.57m | 2.86% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
